Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics ...
Japan's Ministry of Health, Labor and Welfare approves KOSTAIVE®, the first self-amplifying mRNA COVID-19 vaccine for adults 18 and older, targeting the JN.1 lineage of Omicron subvariants. Meiji Seika Pharma, CSL's partner in Japan, will distribute the vaccine in time for the October COVID-19 vaccination campaign.
Reference News
Japan's Ministry of Health, Labor and Welfare approves KOSTAIVE®, the first self-amplifying mRNA COVID-19 vaccine for adults 18 and older, targeting the JN.1 lineage of Omicron subvariants. Meiji Seika Pharma, CSL's partner in Japan, will distribute the vaccine in time for the October COVID-19 vaccination campaign.
CSL and Arcturus Therapeutics' KOSTAIVE®, the first self-amplifying mRNA COVID-19 vaccine, was approved for adults in Japan, targeting the JN.1 Omicron subvariants, with distribution starting in October.